Last reviewed · How we verify
IV diazepam
IV diazepam, marketed by Shaheed Zulfiqar Ali Bhutto Medical University, is a well-established treatment in the pharmaceutical market. The key composition patent is set to expire in 2028, providing a significant period of market exclusivity. The primary risk lies in potential competition once the patent expires, which could erode market share and revenue.
At a glance
| Generic name | IV diazepam |
|---|---|
| Also known as | valium |
| Sponsor | Shaheed Zulfiqar Ali Bhutto Medical University |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- A Study to Assess the Time to Onset of Action of Staccato Alprazolam Versus Midazolam and Diazepam in Healthy Participants (PHASE1)
- Erector Spinae Plane Block vs Quadratus Lumborum Block for Laparoscopic Nephrectomy (NA)
- Prospective Opioid-Free AIS Fusion (PHASE4)
- Efficacy of Ketorolac for Postoperative Pain Management in Hip Arthroscopy: A Prospective Double-Blinded Randomized Controlled Trial (PHASE4)
- Intramuscular Midazolam Versus Intravenous Diazepam for Acute Seizure in Children (EARLY_PHASE1)
- Phenobarbital for Severe Acute Alcohol Withdrawal Syndrome (NA)
- Comparing the Efficacy of Intranasal Midazolam Versus Intravenous Diazepam for Control of Seizures in Children (PHASE4)
- Bioequivalence & Food Effect Study in Patients With Solid Tumor or Hematologic Malignancies (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- IV diazepam CI brief — competitive landscape report
- IV diazepam updates RSS · CI watch RSS
- Shaheed Zulfiqar Ali Bhutto Medical University portfolio CI